View source for NYC medical weight loss

{{Short description|NYC medical weight loss options including GLP-1 injections, oral incretin medications, traditional diet pills, nutrition counseling, sleep medicine, and W8MD long-term maintenance care}}
{{Infobox medical intervention
| name         = NYC medical weight loss
| image        = Confused.jpeg
| caption      = NYC medical weight loss combines physician-supervised treatment, prescription medications, nutrition, sleep care, and long-term maintenance
| specialty    = [[Obesity medicine]], [[medical weight loss]], [[sleep medicine]], [[nutrition]], [[lifestyle medicine]]
| uses         = [[Obesity]], [[overweight]], [[weight loss]], [[weight loss maintenance]], [[insulin resistance]], [[prediabetes]], [[type 2 diabetes]], [[sleep apnea]], [[metabolic syndrome]]
| methods      = [[GLP-1 weight loss injections]], [[incretin therapy]], [[diet pills]], [[nutrition counseling]], [[meal replacements]], [[low-carbohydrate diet]], [[ketogenic diet]], [[sleep apnea]] testing
| providers    = [[Obesity medicine physician]], [[bariatrician]], [[physician]], [[nurse practitioner]]
| related      = [[W8MD Weight Loss, Sleep and MedSpa]], [[personalized weight loss plan]], [[GLP-1 maintenance therapy]], [[long-term weight maintenance]]
}}
[[File:Before-and-after-weight-loss.jpeg|thumb|right|300px|[[NYC medical weight loss]] can help patients lose weight safely and build a long-term [[weight loss maintenance]] plan.]]
[[File:W8md weight loss sleep and medspa team.jpeg|thumb|right|350px|[[W8MD Weight Loss, Sleep and MedSpa]] has provided physician-supervised weight loss, sleep medicine, and wellness care since 2011.]]
[[File:Woman-losing-weight.jpeg|thumb|right|350px|Modern NYC medical weight loss may include [[GLP-1 weight loss injections]], oral incretin medications, traditional [[diet pills]], nutrition counseling, and customized maintenance care.]]
[[File:W8md-meal-replacementnts.png|thumb|right|350px|[[Meal replacements]] may help selected patients with protein intake, portion control, affordability, and structure.]]
[[File:Weight-loss-success-stories-1.jpeg|thumb|right|300px|W8MD success stories include patients who lost more than 100 pounds and maintained long-term results.]]
[[File:Sleep apnea.png|thumb|right|350px|[[Sleep apnea]] evaluation is important because poor sleep can worsen hunger, cravings, fatigue, [[hypertension]], and [[insulin resistance]].]]

'''NYC medical weight loss''' refers to physician-supervised [[weight loss]] care in [[New York City]] for patients with [[obesity]], [[overweight]], [[insulin resistance]], [[prediabetes]], [[type 2 diabetes]], [[metabolic syndrome]], [[sleep apnea]], [[hypertension]], [[fatty liver disease]], [[PCOS]], and related conditions. Unlike commercial diet programs, medical weight loss evaluates the medical causes of weight gain and uses evidence-based tools such as [[nutrition counseling]], [[meal replacements]], [[anti-obesity medication]], [[GLP-1 weight loss injections]], [[incretin therapy]], [[sleep apnea]] screening, and long-term [[weight loss maintenance]].

'''[[W8MD Weight Loss, Sleep and MedSpa]]''' is a physician-supervised NYC medical weight loss, sleep, and wellness center established in 2011. W8MD has helped thousands of patients lose weight and keep it off, including major success stories such as a patient who lost over 165 pounds and other patients who lost over 100 pounds and maintained their results long term. W8MD serves [[New York City]], [[Brooklyn]], [[Queens]], [[Manhattan]], [[Staten Island]], [[Long Island]], [[New Jersey]], [[Connecticut]], and the greater New York metropolitan area.

==Overview==
NYC medical weight loss is designed for patients who need more than a generic diet. Many patients struggle with weight because of appetite biology, [[food noise]], cravings, [[insulin resistance]], poor sleep, untreated [[sleep apnea]], medications, stress, menopause, limited time, cultural food patterns, repeated dieting, or metabolic adaptation after prior weight loss.

A medical weight loss program may include:

{{div col|colwidth=18em}}
* Complete medical evaluation
* [[Body mass index]] assessment
* [[Body composition analysis]]
* Weight history
* Medication review
* [[Nutrition counseling]]
* [[Meal replacements]]
* [[Low-carbohydrate diet]]
* [[Ketogenic diet]]
* [[GLP-1 weight loss injections]]
* Oral incretin medications
* Traditional prescription [[diet pills]]
* [[Sleep apnea]] screening
* [[Home sleep test]]
* [[Microdosing]] and maintenance discussions
* [[Long-term weight maintenance]]
{{div col end}}

==Why choose physician-supervised medical weight loss in NYC?==
New York City patients often face long work hours, stress, restaurant eating, commuting, poor sleep, irregular schedules, and limited time for meal preparation. Physician-supervised medical weight loss can help by combining medical evaluation with realistic nutrition and medication options.

Physician supervision is especially important for patients with:

{{div col|colwidth=18em}}
* [[Obesity]]
* [[Overweight]]
* [[Prediabetes]]
* [[Type 2 diabetes]]
* [[Hypertension]]
* [[Dyslipidemia]]
* [[Heart disease]]
* [[Sleep apnea]]
* [[Fatty liver disease]]
* [[PCOS]]
* [[Binge eating]]
* Medication-related weight gain
* Prior failed diet attempts
* Weight regain after GLP-1 discontinuation
{{div col end}}

The [[National Institute of Diabetes and Digestive and Kidney Diseases]] notes that prescription weight-management medications may be used with lifestyle changes in selected adults with obesity or overweight and weight-related health problems.{{cite web|url=https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity|title=Prescription Medications to Treat Overweight and Obesity|publisher=National Institute of Diabetes and Digestive and Kidney Diseases|accessdate=June 29, 2026}}

==W8MD NYC medical weight loss program==
[[W8MD Weight Loss, Sleep and MedSpa]] provides an integrated approach that combines [[obesity medicine]], [[medical weight loss]], [[nutrition counseling]], [[GLP-1 weight loss injections]], traditional prescription medications, [[sleep medicine]], [[meal replacements]], and maintenance planning.

W8MD may help patients with:

{{div col|colwidth=20em}}
* [[Personalized weight loss plan]]
* [[Physician-supervised weight loss]]
* [[GLP-1 weight loss injections]]
* [[Semaglutide]]
* [[Wegovy]]
* [[Ozempic]]
* [[Tirzepatide]]
* [[Mounjaro]]
* [[Zepbound]]
* [[Foundayo]]
* [[Oral Wegovy]]
* [[Phentermine]]
* [[Phentermine/topiramate]]
* [[Qsymia]]
* [[Contrave]]
* [[Diethylpropion]]
* [[Phendimetrazine]]
* [[Meal replacements]]
* [[Nutrition counseling]]
* [[Sleep apnea]] screening
* [[Home sleep test]]
* [[GLP-1 maintenance therapy]]
* [[Microdosing]]
* [[Long-term weight maintenance]]
{{div col end}}

==Prescription weight loss options==
Prescription weight-loss medications can be grouped into several categories. Some are FDA-approved for chronic weight management, some are approved for short-term use, and some are used off-label in selected patients. Medication choice depends on medical history, BMI, blood pressure, diabetes status, heart history, sleep, medications, pregnancy plans, insurance coverage, cost, side effects, and patient preference.

==Current GLP-1 and incretin-based options==
[[GLP-1 weight loss injections]] and related [[incretin therapy]] have transformed modern obesity medicine. These medications may reduce appetite, increase satiety, reduce food noise, slow gastric emptying, improve blood sugar control, and help selected patients lose significant weight.

{| class="wikitable"
! Medication
! Brand names
! Type
! Main use
! Notes
|-
| [[Semaglutide]]
| [[Wegovy]], [[Ozempic]], [[Rybelsus]]
| [[GLP-1 receptor agonist]]
| Chronic weight management or diabetes depending on product
| Wegovy is used for chronic weight management; Ozempic and Rybelsus are primarily diabetes brands
|-
| [[Tirzepatide]]
| [[Zepbound]], [[Mounjaro]]
| Dual [[GIP]]/[[GLP-1]] receptor agonist
| Chronic weight management, diabetes, and OSA indication depending on product
| Zepbound is approved for chronic weight management and moderate-to-severe OSA in adults with obesity
|-
| [[Liraglutide]]
| [[Saxenda]], [[Victoza]]
| [[GLP-1 receptor agonist]]
| Weight management or diabetes depending on product
| Saxenda is a daily injection for chronic weight management
|-
| [[Oral semaglutide]]
| [[Oral Wegovy]], [[Rybelsus]]
| Oral [[GLP-1 receptor agonist]]
| Weight management or diabetes depending on product
| Wegovy tablets are FDA-approved for adult weight management
|-
| [[Orforglipron]]
| [[Foundayo]]
| Oral small-molecule [[GLP-1 receptor agonist]]
| Chronic weight management
| FDA-approved in 2026 for adults with obesity or overweight with weight-related comorbidity
|}

The FDA approved [[Zepbound]] or [[tirzepatide]] for chronic weight management in adults with obesity or overweight with at least one weight-related condition, together with reduced-calorie diet and increased physical activity.{{cite web|url=https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management|title=FDA Approves New Medication for Chronic Weight Management|publisher=U.S. Food and Drug Administration|date=November 8, 2023|accessdate=June 29, 2026}}

The FDA approved [[Zepbound]] as the first medication for moderate-to-severe [[obstructive sleep apnea]] in adults with obesity.{{cite web|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea|title=FDA Approves First Medication for Obstructive Sleep Apnea|publisher=U.S. Food and Drug Administration|date=December 20, 2024|accessdate=June 29, 2026}}

The FDA approved [[Wegovy]] to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.{{cite web|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or|title=FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight|publisher=U.S. Food and Drug Administration|date=March 8, 2024|accessdate=June 29, 2026}}

FDA labeling for [[Wegovy]] tablets states that oral semaglutide is indicated with reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight with at least one weight-related comorbid condition.{{cite web|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf|title=WEGOVY tablets prescribing information|publisher=U.S. Food and Drug Administration|accessdate=June 29, 2026}}

The FDA novel drug approvals list for 2026 includes [[Foundayo]] or [[orforglipron]] to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight with at least one weight-related comorbid condition, in combination with reduced-calorie diet and increased physical activity.{{cite web|url=https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026|title=Novel Drug Approvals for 2026|publisher=U.S. Food and Drug Administration|accessdate=June 29, 2026}}

==Traditional prescription diet pills==
Traditional prescription [[diet pills]] remain useful for selected patients, especially those who are not candidates for GLP-1 therapy, need a lower-cost option, need combination maintenance, or respond well to appetite-suppressing medications.

{| class="wikitable"
! Medication
! Brand or class
! Type
! Common role in medical weight loss
|-
| [[Phentermine]]
| Adipex-P and generics
| Sympathomimetic appetite suppressant
| Short-term appetite control in selected patients
|-
| [[Phentermine/topiramate]]
| [[Qsymia]]
| Combination medication
| Chronic weight management
|-
| [[Naltrexone/bupropion]]
| [[Contrave]]
| Appetite and reward pathway medication
| Chronic weight management, especially cravings in selected patients
|-
| [[Orlistat]]
| [[Xenical]], Alli
| Gastrointestinal lipase inhibitor
| Reduces dietary fat absorption
|-
| [[Diethylpropion]]
| Tenuate and generics
| Sympathomimetic anorectic
| Short-term appetite suppression in selected patients
|-
| [[Phendimetrazine]]
| Bontril and generics
| Sympathomimetic anorectic
| Short-term appetite suppression in selected patients
|-
| [[Topiramate]]
| Generic
| Anticonvulsant used off-label
| May help cravings or binge-type eating in selected patients
|-
| [[Metformin]]
| Generic
| Insulin-sensitizing diabetes medication
| May help selected patients with insulin resistance, prediabetes, PCOS, or diabetes
|}

The NIDDK lists FDA-approved long-term weight-management medications including orlistat, phentermine-topiramate, naltrexone-bupropion, liraglutide, semaglutide, and tirzepatide.{{cite web|url=https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity|title=Prescription Medications to Treat Overweight and Obesity|publisher=National Institute of Diabetes and Digestive and Kidney Diseases|accessdate=June 29, 2026}}

DailyMed labeling for [[Contrave]] states that it is indicated as an adjunct to reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity or overweight with at least one weight-related comorbid condition.{{cite web|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9889a75d-4197-496c-aae1-15c9058c1d1b|title=CONTRAVE prescribing information|publisher=DailyMed, National Library of Medicine|accessdate=June 29, 2026}}

DailyMed labeling for [[phentermine]] notes that dosage should be individualized to obtain adequate response with the lowest effective dose.{{cite web|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3b44d104-a7d0-4366-9d42-63f784f3cb22|title=Phentermine hydrochloride tablet prescribing information|publisher=DailyMed, National Library of Medicine|accessdate=June 29, 2026}}

==Emerging and investigational weight loss medications==
The obesity medication pipeline is expanding rapidly. Emerging medications may offer oral dosing, monthly dosing, multiple hormone targets, or higher weight-loss potential. These should be considered investigational unless approved by the FDA.

{| class="wikitable"
! Medication
! Developer/class
! Status
! Notes
|-
| [[Retatrutide]]
| Triple [[GIP]]/[[GLP-1]]/glucagon receptor agonist
| Investigational
| Lilly describes retatrutide as an investigational once-weekly triple hormone receptor agonist; phase 3 trials have been reported or are ongoing
|-
| [[CagriSema]]
| [[Cagrilintide]] plus [[semaglutide]]
| Investigational or regulatory review depending on date
| Combination of an amylin analog and GLP-1 receptor agonist studied for obesity
|-
| [[Amycretin]]
| GLP-1 and amylin receptor agonist
| Investigational
| Also known as zenagamtide; under clinical development for obesity and type 2 diabetes
|-
| [[MariTide]]
| Maridebart cafraglutide
| Investigational
| Monthly or less frequent injectable therapy being studied for obesity and related conditions
|-
| Higher-dose or next-generation semaglutide products
| GLP-1 receptor agonist
| Product-specific status varies
| May be considered when FDA-approved and medically appropriate
|}

Lilly describes [[retatrutide]] as an investigational once-weekly triple hormone receptor agonist that activates receptors for GIP, GLP-1, and glucagon.{{cite web|url=https://www.lilly.com/news/stories/what-to-know-about-retatrutide|title=What to know about retatrutide|publisher=Eli Lilly and Company|accessdate=June 29, 2026}}

A phase 2 trial of [[retatrutide]] published in the ''New England Journal of Medicine'' reported substantial weight reduction in adults with obesity over 48 weeks.{{cite journal|last1=Jastreboff|first1=A. M.|title=Triple-Hormone-Receptor Agonist Retatrutide for Obesity|journal=New England Journal of Medicine|year=2023|doi=10.1056/NEJMoa2301972|pmid=37366315}}

A 2025 ''New England Journal of Medicine'' trial reported that coadministered [[cagrilintide]] and [[semaglutide]], or [[CagriSema]], produced clinically meaningful body-weight reductions in adults with overweight or obesity compared with placebo.{{cite journal|last1=Wharton|first1=S.|title=Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity|journal=New England Journal of Medicine|year=2025|doi=10.1056/NEJMoa2502081}}

Novo Nordisk has described [[amycretin]], also known as [[zenagamtide]], as a unimolecular GLP-1 and amylin receptor agonist under clinical development for adults with type 2 diabetes and adults with overweight or obesity.{{cite web|url=https://www.prnewswire.com/news-releases/novo-nordisks-investigational-zenagamtide-shows-significant-a1c-reductions-with-up-to-14-6-weight-loss-in-adults-with-type-2-diabetespresented-at-ada-2026--302793124.html|title=Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes|publisher=Novo Nordisk|date=June 5, 2026|accessdate=June 29, 2026}}

Amgen describes [[MariTide]] or maridebart cafraglutide as an investigational therapy being studied for obesity and obesity-related conditions.{{cite web|url=https://www.amgen.com/stories/2026/05/the-story-of-maridebart-cafraglutide|title=The Story of Maridebart Cafraglutide|publisher=Amgen|accessdate=June 29, 2026}}

==How W8MD helps patients lose weight==
W8MD helps patients by building a physician-supervised plan rather than relying on a single medication or generic diet. The program may combine medication, nutrition, sleep care, behavioral support, and maintenance.

W8MD may help with:

{{div col|colwidth=20em}}
* Medical obesity evaluation
* [[Personalized weight loss plan]]
* Prescription medication selection
* GLP-1 and incretin therapy evaluation
* Traditional diet pill evaluation
* Insurance and prior authorization support when available
* [[Nutrition counseling]]
* [[Meal replacements]]
* [[W8MD weight loss diet]]
* [[Low-carbohydrate diet]]
* [[Ketogenic diet]]
* [[Sleep apnea]] screening
* [[Home sleep test]]
* [[CPAP]] support
* [[Microdosing]] and maintenance discussions
* [[Long-term weight maintenance]]
{{div col end}}

==How W8MD helps patients keep weight off==
Long-term success requires a maintenance plan. Many patients regain weight after stopping medication or losing follow-up structure. W8MD helps patients transition from active weight loss to maintenance.

Maintenance options may include:

{{div col|colwidth=20em}}
* [[GLP-1 maintenance therapy]]
* Lowest effective dose strategy
* Clinician-guided [[microdosing]] discussions
* Extended interval dosing discussions when appropriate
* Prescription diet pill maintenance when appropriate
* Protein-first nutrition
* Meal replacements
* Weekly weight monitoring
* Sleep apnea treatment
* Strength training support
* Early intervention for weight regain
* Long-term follow-up visits
{{div col end}}

The STEP 1 trial extension found that after withdrawal of once-weekly semaglutide 2.4 mg and lifestyle intervention, participants regained a substantial portion of lost weight.{{cite journal|last1=Wilding|first1=J. P. H.|title=Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension|journal=Diabetes, Obesity and Metabolism|year=2022|pmid=35441470|pmc=9542252}}

In SURMOUNT-4, continued [[tirzepatide]] helped maintain weight reduction, while withdrawal led to substantial weight regain in many participants.{{cite journal|last1=Aronne|first1=L. J.|title=Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity|journal=JAMA|year=2024|pmid=38078870}}

==W8MD success stories and testimonials==
W8MD has helped thousands of patients since 2011. The program has reported major success stories, including a biggest-loser result of more than 165 pounds lost and multiple patients who lost over 100 pounds and maintained their results for years. Individual results vary, and no specific amount of weight loss can be guaranteed.

===Featured W8MD patient success story===
<div style="border:2px solid #b7d7a8;background:linear-gradient(135deg,#f7fff3,#ffffff);padding:18px;margin:14px 0 20px 0;border-radius:12px;">
<h2 style="margin-top:0;color:#38761d;">Fantastic program. Truly a life changer.</h2>
<blockquote style="font-size:112%;line-height:1.7;margin:0;">
'''“FANTASTIC program! Truly a life changer! The first several months I lost on average 3 pounds a week. I have now lost 87 pounds in 10 months and I'm still losing! I can say it feels almost effortless, for with the elimination of most carbs plus the medication I have ZERO cravings and minimal hunger. My cholesterol, blood pressure, and blood sugar have all returned to normal having previously been considerably elevated. I look and feel twenty years younger (I am 57.) Staff is friendly and supportive, and the science works. I did not think that I would be able to achieve such results, and certainly not in less than a year. I am amazed at my success, and I could not have done it without Dr. Tumpati and W8MD.”'''
</blockquote>
<p style="font-size:105%;line-height:1.6;margin-bottom:0;">
'''- D.M., actual W8MD patient''' who lost '''100 lbs''' and has maintained the weight loss for over '''10 years'''.
</p>
</div>

===W8MD result themes===
Patients who succeed with W8MD often report:

{{div col|colwidth=18em}}
* Reduced hunger
* Reduced cravings
* Less food noise
* Better portion control
* Improved energy
* Improved blood pressure
* Improved blood sugar
* Improved cholesterol
* Better sleep
* Better mobility
* More confidence
* Long-term maintenance support
{{div col end}}

==Affordable NYC medical weight loss options==
<div style="border:2px solid #f2c94c;background:#fff8df;padding:14px;margin:12px 0;border-radius:10px;">
'''Affordable NYC medical weight loss and GLP-1 options'''

[[W8MD Weight Loss, Sleep and MedSpa]] offers affordable physician-supervised medical weight-loss options for eligible patients.

* '''Affordable GLP-1 options starting at $29.99/week and up''' with insurance for visits for eligible patients.
* '''Most insurances accepted''' for qualifying medical visits.
* '''Self-pay GLP-1 injection options starting from $59.99/week and up''' when available and medically appropriate.
* Medication access, pricing, insurance coverage, prior authorization, and eligibility vary by patient, medication, pharmacy availability, location, and medical evaluation.
</div>

==W8MD Brooklyn / NYC location==
{| class="wikitable" style="width:100%;"
! Location
! Address
! Phone
! Services
! Map
|-
| '''[[NYC medical weight loss|Brooklyn / New York City Weight Loss Center]]'''
| 2632 E 21st Street, Suite L3, Brooklyn, NY 11235
| (718) 946-5500
| [[Medical weight loss]], [[GLP-1 weight loss injections]], [[sleep medicine]], [[MedSpa]], [[nutrition counseling]], [[meal replacements]]
| [https://www.google.com/maps/search/?api=1&query=2632+E+21st+Street+Ste+L3+Brooklyn+NY+11235 View map]
|}

==NYC and nearby service areas==
{{div col|colwidth=18em}}
* [[New York City weight loss]]
* [[Greater New York City weight loss]]
* [[Brooklyn weight loss]]
* [[Manhattan weight loss]]
* [[Queens weight loss]]
* [[Staten Island weight loss]]
* [[Bronx weight loss]]
* [[Long Island weight loss]]
* [[Nassau County weight loss]]
* [[Suffolk County weight loss]]
* [[New Jersey weight loss]]
* [[Jersey City weight loss]]
* [[Hoboken weight loss]]
* [[Connecticut weight loss]]
* [[Telemedicine weight loss]]
{{div col end}}

==Who may benefit from NYC medical weight loss?==
Patients may benefit if they have:

{{div col|colwidth=18em}}
* BMI of 30 or higher
* BMI of 27 or higher with weight-related conditions
* Repeated diet failure
* Weight regain after GLP-1 medication
* Strong hunger or cravings
* [[Prediabetes]]
* [[Type 2 diabetes]]
* [[Insulin resistance]]
* [[Metabolic syndrome]]
* [[Sleep apnea]]
* [[Hypertension]]
* [[High cholesterol]]
* [[Fatty liver disease]]
* [[PCOS]]
* Need for long-term maintenance
{{div col end}}

==Safety and monitoring==
Prescription weight-loss medications require medical supervision. W8MD may monitor:

{{div col|colwidth=18em}}
* Weight trend
* Blood pressure
* Pulse
* Side effects
* Appetite
* Cravings
* Blood sugar when appropriate
* Constipation
* Nausea
* Hydration
* Sleep symptoms
* Medication interactions
* Pregnancy plans when relevant
* Maintenance readiness
{{div col end}}

==Frequently asked questions==
===What is NYC medical weight loss?===
NYC medical weight loss is physician-supervised treatment for obesity and overweight using medical evaluation, nutrition counseling, prescription medications, sleep care, and long-term maintenance.

===Does W8MD offer GLP-1 weight loss injections in NYC?===
Yes. W8MD can evaluate eligible patients for GLP-1 and incretin-based medications such as semaglutide, Wegovy, Ozempic, tirzepatide, Mounjaro, Zepbound, oral Wegovy, and Foundayo when medically appropriate.

===Does W8MD offer traditional diet pills?===
Yes. W8MD may evaluate selected patients for medications such as phentermine, phentermine/topiramate, Contrave, diethylpropion, phendimetrazine, topiramate, metformin, and other options when medically appropriate.

===Can W8MD help patients keep weight off?===
Yes. W8MD emphasizes long-term weight maintenance using follow-up care, nutrition counseling, meal replacements, GLP-1 maintenance therapy, clinician-guided microdosing discussions, prescription medication adjustment, and sleep apnea care.

===Does W8MD help with sleep apnea?===
Yes. W8MD provides sleep medicine services including sleep apnea screening and home sleep testing when appropriate. Treating sleep apnea can help improve fatigue, appetite control, blood pressure, and metabolic health.

===Does W8MD accept insurance?===
Yes. W8MD accepts most insurances for qualifying medical visits when coverage is available. Coverage varies by plan, diagnosis, medication, prior authorization rules, copay, and deductible.

===What makes W8MD different from a commercial diet program?===
W8MD uses physician-supervised obesity medicine, prescription medication options, sleep medicine, nutrition counseling, meal replacements, GLP-1 therapy when appropriate, and long-term maintenance planning rather than a one-size-fits-all diet.

==Conclusion==
NYC medical weight loss is a comprehensive, evidence-based approach for patients who want to lose weight safely and keep it off. [[W8MD Weight Loss, Sleep and MedSpa]], established in 2011, has helped thousands of patients through physician-supervised obesity medicine, GLP-1 weight-loss injections, oral incretin medications, traditional diet pills, nutrition counseling, meal replacements, sleep apnea care, and personalized maintenance plans. With major patient success stories, including a biggest loser who lost over 165 pounds and patients such as D.M. who lost over 100 pounds and maintained long-term results, W8MD offers a practical medical pathway for New York City patients seeking lasting weight-loss success.

==See also==
{{div col|colwidth=18em}}
* [[NYC medical weight loss]]
* [[New York City weight loss]]
* [[Brooklyn weight loss]]
* [[Medical weight loss]]
* [[Physician-supervised weight loss]]
* [[Obesity medicine]]
* [[Personalized weight loss plan]]
* [[Nutrition counseling]]
* [[Long-term weight maintenance]]
* [[GLP-1 maintenance therapy]]
* [[Microdosing]]
* [[GLP-1 weight loss]]
* [[Incretin therapy]]
* [[Semaglutide]]
* [[Wegovy]]
* [[Ozempic]]
* [[Tirzepatide]]
* [[Mounjaro]]
* [[Zepbound]]
* [[Oral Wegovy]]
* [[Foundayo]]
* [[Retatrutide]]
* [[CagriSema]]
* [[Amycretin]]
* [[MariTide]]
* [[Phentermine]]
* [[Phentermine/topiramate]]
* [[Qsymia]]
* [[Contrave]]
* [[Diethylpropion]]
* [[Phendimetrazine]]
* [[Meal replacements]]
* [[Sleep apnea]]
* [[W8MD Weight Loss, Sleep and MedSpa]]
{{div col end}}

==Relevant WikiMD links==
* [https://wikimd.org/wiki/NYC_medical_weight_loss NYC medical weight loss on WikiMD]
* [https://wikimd.org/wiki/Medical_weight_loss Medical weight loss on WikiMD]
* [https://wikimd.org/wiki/Physician-supervised_weight_loss Physician-supervised weight loss on WikiMD]
* [https://wikimd.org/wiki/Obesity_medicine Obesity medicine on WikiMD]
* [https://wikimd.org/wiki/GLP-1_weight_loss GLP-1 weight loss on WikiMD]
* [https://wikimd.org/wiki/Semaglutide Semaglutide on WikiMD]
* [https://wikimd.org/wiki/Tirzepatide Tirzepatide on WikiMD]
* [https://wikimd.org/wiki/Zepbound Zepbound on WikiMD]
* [https://wikimd.org/wiki/Wegovy Wegovy on WikiMD]
* [https://wikimd.org/wiki/Phentermine Phentermine on WikiMD]
* [https://wikimd.org/wiki/Contrave Contrave on WikiMD]
* [https://wikimd.org/wiki/Weight_loss_maintenance Weight loss maintenance on WikiMD]
* [https://wikimd.org/wiki/Sleep_apnea Sleep apnea on WikiMD]

==Further reading==
* {{cite web|url=https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity|title=Prescription Medications to Treat Overweight and Obesity|publisher=National Institute of Diabetes and Digestive and Kidney Diseases|accessdate=June 29, 2026}}
* {{cite web|url=https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management|title=FDA Approves New Medication for Chronic Weight Management|publisher=U.S. Food and Drug Administration|date=November 8, 2023|accessdate=June 29, 2026}}
* {{cite web|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea|title=FDA Approves First Medication for Obstructive Sleep Apnea|publisher=U.S. Food and Drug Administration|date=December 20, 2024|accessdate=June 29, 2026}}
* {{cite web|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or|title=FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight|publisher=U.S. Food and Drug Administration|date=March 8, 2024|accessdate=June 29, 2026}}
* {{cite web|url=https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026|title=Novel Drug Approvals for 2026|publisher=U.S. Food and Drug Administration|accessdate=June 29, 2026}}
* {{cite web|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf|title=WEGOVY tablets prescribing information|publisher=U.S. Food and Drug Administration|accessdate=June 29, 2026}}
* {{cite web|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9889a75d-4197-496c-aae1-15c9058c1d1b|title=CONTRAVE prescribing information|publisher=DailyMed, National Library of Medicine|accessdate=June 29, 2026}}
* {{cite web|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3b44d104-a7d0-4366-9d42-63f784f3cb22|title=Phentermine hydrochloride tablet prescribing information|publisher=DailyMed, National Library of Medicine|accessdate=June 29, 2026}}
* {{cite journal|last1=Wilding|first1=J. P. H.|title=Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension|journal=Diabetes, Obesity and Metabolism|year=2022|pmid=35441470|pmc=9542252}}
* {{cite journal|last1=Aronne|first1=L. J.|title=Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity|journal=JAMA|year=2024|pmid=38078870}}
* {{cite journal|last1=Jastreboff|first1=A. M.|title=Triple-Hormone-Receptor Agonist Retatrutide for Obesity|journal=New England Journal of Medicine|year=2023|doi=10.1056/NEJMoa2301972|pmid=37366315}}

==External links==
* [https://www.w8mdspa.com W8MD Weight Loss, Sleep and Medspa Centers]
* [https://nycmedicalweightloss.com NYC medical weight loss]
* [https://w8md.org Philadelphia medical weight loss]
* [https://wikimd.org/wiki/NYC_medical_weight_loss NYC medical weight loss on WikiMD]
* [https://wikimd.org/wiki/Medical_weight_loss Medical weight loss on WikiMD]
* [https://wikimd.org/wiki/GLP-1_weight_loss GLP-1 weight loss on WikiMD]
* [https://wikimd.org/wiki/Weight_loss_maintenance Weight loss maintenance on WikiMD]
* [https://wikimd.org/wiki/Sleep_apnea Sleep apnea on WikiMD]

{{W8MD}}
{{DEFAULTSORT:NYC Medical Weight Loss}}
[[Category:NYC medical weight loss]]
[[Category:New York City weight loss]]
[[Category:Brooklyn weight loss]]
[[Category:Medical weight loss]]
[[Category:Physician-supervised weight loss]]
[[Category:Obesity medicine]]
[[Category:Weight loss]]
[[Category:Weight loss maintenance]]
[[Category:Long-term weight maintenance]]
[[Category:Personalized weight loss plan]]
[[Category:Nutrition counseling]]
[[Category:Meal replacements]]
[[Category:GLP-1 weight loss]]
[[Category:Incretin therapy]]
[[Category:GLP-1 maintenance therapy]]
[[Category:Microdosing]]
[[Category:Semaglutide]]
[[Category:Wegovy]]
[[Category:Ozempic]]
[[Category:Tirzepatide]]
[[Category:Mounjaro]]
[[Category:Zepbound]]
[[Category:Foundayo]]
[[Category:Orforglipron]]
[[Category:Retatrutide]]
[[Category:CagriSema]]
[[Category:Amycretin]]
[[Category:MariTide]]
[[Category:Phentermine]]
[[Category:Phentermine/topiramate]]
[[Category:Qsymia]]
[[Category:Contrave]]
[[Category:Diethylpropion]]
[[Category:Phendimetrazine]]
[[Category:Sleep apnea]]
[[Category:Insulin resistance]]
[[Category:Prediabetes]]
[[Category:Type 2 diabetes]]
[[Category:W8MD]]
__NOTOC__